table network network 2
demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only
COVID 19 hospitalized
COVID 19 all comers
Immunosuppressants drugs
anti-interleukin-6
sarilumab
sarilumab high dose (400mg) sarilumab phase 2 high dose
sarilumab low dose (200mg) sarimulab phase 2 low dose
tocilizumab BACC Bay Tocilizumab Trial TOCOVID
janus kinase (JAK) inhibitor
baricitinib RECOVERY

6 studies excluded by filtering options 1

5357 Cavalli, 2020 0130selection pending
5398 Ana-COVID (Huet), 2020 0133selection pending
5523 Toniati, 2020 2990excludednot a RCTrisk of bias not avaialble
5526 Price, 2020 2130excludednot a RCTrisk of bias not avaialble
6020 Annane, 2020 0130selection pending
6359 Kooistra, 2020 0100selection pending

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons